In the present study, PCOS phenotypes and dyslipidemia were observed in animals that received letrozole, which were confirmed by increased testosterone (hyperandrogenism) and AMH levels, 17-β estradiol depletion and impaired androgen clearance (SHBG) with multiple ovarian cysts, as well as disrupted lipid profile compared with control animals. This evidence concerns the gene SHBG and polycystic ovary syndrome.